Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1238 Features
Biotech boom for Japan?

15 Aug 03

Some of the world’s leading drugs, such as Bristol-Myers Squibb’s pravastatin for high cholesterol, TAP’s lansoprazole and Daiichi’s levofloxacin were discovered in Japanese laboratories. With this history of important drug research there is keen interest in biotechnology.
Dr Faiz Kermani

Pharma’s Fastest Growing Customer Base

15 Aug 03

The increase in life expectancy coupled with a decreasing birth rate will place considerable pressure on governments and healthcare providers. Governments are having to reassess how they allocate their healthcare spending given that on average, the over 65s require four times as much healthcare resources as younger people.
Dr Faiz Kermani

The Kv1.3 potassium channel as a target for multip

05 Aug 03

Research towards the development of ion channel modulators is booming. One exciting target is the Kv1.3 voltage activated potassium channel. Expressed by human T lymphocytes Kv1.3 is involved in proliferation and cytokine secretion. Animal studies have established Kv1.3 as a target for the unmet multiple sclerosis (MS) market. Further key proof of concept data has now emerged demonstrating the selective expression of this channel in myelin-reactive effector memory T cells from MS patients
LeadDiscovery

Pharma NewsBytes (August, 2003)

05 Aug 03

Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
LeadDiscovery

Pharmaceutical Marketing: The Internet impact

29 Jul 03

Faced with rising costs, shortened product lifecycles and an increasing reliance on blockbuster drugs, pharmaceutical companies are turning towards innovative marketing campaigns and new channels to reach an increasingly demanding consumer audience. Offering particular potential, campaign management solutions are being introduced to establish profitable interactions with large numbers of consumers across multiple channels.
Michael Randle

Cancer: an old problem

29 Jul 03

Although elderly people have a higher incidence of the four major cancers than any other age group, there is a fundamental lack of knowledge regarding the treatment of this demographic, resulting in their under-treatment. Commercial opportunity therefore awaits any pharmaceutical company able to target the development of strategies aimed specifically at elderly patients.
Michael Randle

HDAC7 : A novel target for autoimmune disorders

07 Jul 03

The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscovery’s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
LeadDiscovey

Idec and Biogen: a natural union?

30 Jun 03

Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made earlier this week. The deal will create the third largest biotech firm in the world, yet Wall Street has so far appeared unimpressed by the deal. Even individual analysts seem to be disagreeing as to the strategic sense of the partnership.
Michael Randle

Partnerships in Clinical Research

10 Jun 03

At every stage of the R&D process, the companies must evaluate the time, logistics, expense and expertise that they can allocate. This also entails knowing when to rely on in-house capabilities and wh
Dr Faiz Kermani

Target of the Month

10 Jun 03

Uncontrolled proliferation is a common feature of malignant cells. Proliferation correlates with a nuclear protein known as Ki-67. Researchers have now shown that an antisense oligonucleotide against
LeadDiscovery

The Oncology Collection

03 Jun 03

To mark the American Society of Clinical Oncology's 2003 conference, LeadDiscovery has launched The Oncology Collection. The Oncology Collection groups all of LeadDiscovery's oncology services in one
LeadDiscovery

Zetia: Potential to reshape the cholesterol drug l

30 May 03

Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, wi
Michael Randle

Cymbalta: Eli Lilly to return to antidepressant ma

23 May 03

Eli Lilly and Company is set to launch Cymbalta into the depression and stress urinary incontinence markets in mid-2003. Datamonitor analyzes whether the company most synonymous with the antidepressan
Michael Randle

Australian e-Detailing Market

21 May 03

An extensive study carried out by Frost & Sullivan has revealed the tremendous potential for e-Detailing technology in Australia.
Jessinta Joseph Govan

Advances in ion channel drug discovery

20 May 03

A highly targeted library is available for the screening of potassium channel blockers or potassium channel openers
LeadDiscovery

Successful gene therapy of pulmonary hypertension

20 May 03

Canadian researchers have successfully treated animals with experimental pulmonary hypertension with a vector expressing the Kv1.5 potassium channel gene
LeadDiscovery

The Swiss Success Story

16 May 03

Switzerland has been a major force in the development of new medicines for over a century. Around 5% of current global pharmaceutical R&D is attributable to Swiss companies.
Larry Hughes and Dr Faiz Kermani

AXESS welcomes the second edition of “Careers with

13 May 03

Many of our candidates benefited from the previous book, and we are sure that the new edition will build on this success
Ian Thomas

eHealth News Roundup for April 21st – May 2nd 2003

09 May 03

The healthcare industry has utilized the Internet most recently as both a marketing tool and as a facility to pass on important medical information. Leading drug maker Abbott Laboratories will be look
Michael Randle

Behavioral Disorders: ADHD and beyond

09 May 03

Over the past decade, behavioral disorders have received increasing attention, both from the media and medical professionals, however only attention deficit/hyperactivity disorder has emerged as a key
Michael Randle

Introducing EIM: The key to improving pharmaceutic

08 May 03

Enterprise Incentive Management (EIM) software -improves pharmaceutical sales and provides accurate and timely compensation to both direct and indirect sales people. Already used in the pharmaceutica
David Blume

Biotechnology and the Revitalisation of Drug Devel

02 May 03

The development of novel medicines is critical if diseases and disorders are to be effectively treated. As a result, many have looked to biotechnology to provide continuing innovation in the field of
Pietro Bonacossa and Dr Faiz Kermani

Risk and Reward in R&D

02 May 03

Investing in R&D requires long-term planning and the willingness to take risks. Only about 15% of new drugs entering development subsequently reach the market, and the overall expense can be in the or
Faiz Kermaini & Pietro Bonacossa

Asthma Therapeutics: New treatment options and eme

02 May 03

Asthma drives a large but competitive market. Current therapeutics are generally effective but patient compliance is often poor. Future commercial successes in the asthma arena will likely focus on mo
LeadDiscovery/Prof. Peter Barnes

HIV: Justifying premium pricing

01 May 03

Roche's recent announcement of an EU price point of $20,570 per year for its novel HIV fusion inhibitor Fuzeon has brought the issue of pricing HIV therapies to the fore. Roche's premium pricing strat
Michael Randle

Malaria: The Neglected Disease

30 Apr 03

Malaria kills more people in the world than any other communicable disease except tuberculosis, yet in terms of new drug development the disease is widely seen as a neglected one.
Dr Faiz Kermani

MAPK/ERK-kinase inhibition as a promising strategy

26 Apr 03

Approximately 9% of the US population suffers from moderate to severe non-cancer-related pain, a figure that includes 40-70 million individuals with chronic pain. The development of analgesics represe
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.